Phase 2 N=35 Cabozantinib for Metastatic Triple Negative BrCa
Breast Cancer
Primary: Objective Response Rate — 0.09 proportion of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=64 Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
Breast Cancer · Triple Negative Breast Cancer · Stage IV Breast Cancer
Primary: Objective Response Rate — 28; 38 percentage of patients
Phase 2 N=10 TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer
Triple Negative Breast Cancer
Primary: Efficacy (Objective Response Rate) — 1 Participants
Phase 2 N=30 Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer
Metastatic Triple Negative Breast Cancer
Primary: Overall Response Rate (ORR) in Patients Treated With CNP — 2; 11; 6; 8 Participants
Phase 2 N=50 BKM120 For Triple Negative Breast Cancer
Breast Cancer
Primary: Clinical Benefit Rate — 0.12 proportion of participants
Phase 2 N=10 LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer
Triple Negative Breast Cancer
Primary: Efficacy (Objective Response Rate) — 3 Participants
Phase 2 N=6 Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer
Metastatic Triple Negative Breast Cancer
Primary: Objective Response Rate (ORR) — 0; 1; 1; 4 Participants
Phase 2 N=31 Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Progression Free Survival (PFS) After Treatment With Doxil, Carboplatin and Bevacizumab in Patients With ER, PR, HER2neu Negative Metastatic Breast Cancer — 6 participants
Phase 2 N=71 Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Progression-free Survival (PFS) — 4.4 Months
Phase 2 N=37 Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
Estrogen Receptor Negative · HER2/Neu Negative · Invasive Breast Carcinoma
Primary: Objective Response Rate (ORR), Defined as the Proportion of Patients Who Have Had a Partial Response (PR) or Complete Response (CR) (RECIST 1.1 Based) Within the First 6…
Phase 3 N=182 A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer
Triple-Negative Breast Cancer
Primary: Percentage of Participants With Treatment-emergent Grade ≥3 Adverse Events (AEs) — 46.70 percentage of participants
Phase 2 N=24 Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer
Triple Negative Breast Cancer
Primary: 3 Months Progression Free Survival. Probability That the Cancer Has Not Progressed at 3 Months Calculated With Kaplan Meier. — 15.8 perceent probability at 3 months
Phase 1 N=27 Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer
Estrogen Receptor Negative · HER2/Neu Negative · Progesterone Receptor-negative
Primary: Number of Participants Experiencing a Dose Limiting Toxicity (DLT) (Phase I) and the Recommended Phase IB Dose (RP2D) — 4; 4; 2 Participants
Phase 2 N=86 Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Breast Cancer
Primary: Objective Response Rate — 3; 19; 4; 57 Participants
Phase 2 N=41 Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer
Breast Cancer
Primary: Best Clinical Response Expressed as Percentage of Participants Treated With Combination Regimen of Weekly Abraxane® and Carboplatin Plus Biweekly Bevacizumab to Treat…
Phase 2 N=40 Neo-Adjuvant Study in Triple Negative Breast Cancer Patients
Breast Cancer
Primary: Complete Response Rate — 2; 8 Participants
Phase 2 N=173 Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer
Breast Neoplasm
Primary: Best Overall Response (BOR) — 20.0; 10.3 percentage of participants — p=0.1109
Phase 2 N=17 Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative
Invasive Breast Carcinoma · Triple-Negative Breast Carcinoma
Primary: RCB Status — 0; 1; 13; 3 participants
Phase 2 N=18 A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer
Breast Cancer
Primary: Overall Response Rate — 1 Participants
Phase 2 N=50 A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer
Breast Cancer
Primary: Rate of Clinical Benefit — 0; 0; 6; 11 Participants
Phase 2 N=48 Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer
Triple-negative Breast Cancer
Primary: 3-month Progression-free Survival (3-mo PFS) Rate — 0.511 proportion of participants
Phase 2 N=99 Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
Breast Cancer
Primary: Objective Response Rate (ORR) (Phase II) — 0; 5; 14 Participants
Phase 3 N=651 A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)
Triple-Negative Breast Cancer
Primary: Progression-Free Survival (PFS) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Subpopulation With Programmed Death-Ligand 1…
Phase 2 N=44 A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer
Breast Cancer · Metastasis
Primary: Number of Participants With Complete Response (CR) or Partial Response (PR) — 2; 0 participants
Phase 2 N=217 Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer
Breast Neoplasms
Primary: Progression-Free Survival (PFS) — 2.0; 2.7; 1.7; 2.5 Months — p=0.8885
Phase 3 N=191 Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
Breast Tumor · Breast Cancer · Cancer of the Breast
Primary: Kaplan-Meier Estimates of Progression-Free Survival (PFS) Based on Investigator Assessment. — 5.5; 8.3; 6.0 months — p=0.0183
Phase 2 N=40 Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer
Triple Negative Breast Cancer
Primary: The Progression Free Survival (PFS) — 1.8 months
Phase 2 N=13 Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer
Breast Adenocarcinoma · Metastatic Triple-Negative Breast Carcinoma · Stage III Breast Cancer AJCC v7
Primary: Maximum Tolerated Dose (MTD) of Pembrolizumab in Combination With Binimetinib Using the Standard 3+3 Design (Phase I) — 2; 0; 1; 6 Participants
Phase 2 N=10 Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)
Breast Cancer
Primary: Clinical Benefit Rate — 0; 0; 3; 7 Participants
Phase 2 N=327 Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
Metastatic gpNMB Over-expressing Triple Negative Breast Cancer
Primary: Progression Free Survival (PFS) — 2.8; 2.9 months — p=0.761